ARTICLE | Regulation
A Very Long Walk: Staying the Course
October 19, 2009 7:00 AM UTC
Life looked bleak for Acorda Therapeutics Inc. in 2004, when the company withdrew an IPO and its lead compound Fampridine-SR failed in Phase III trials for spinal cord injury (SCI). But Acorda (NASDAQ...